COMPARE-ABSORB: 3-Year Results Hint at Stabilization With Bioresorbable Scaffold
March 17, 2021 Three-year outcomes from COMPARE-ABSORB hint that the increased risks of thrombosis and target lesion failure with the now-discontinued Absorb bioresorbable scaffold (Abbott Vascular) do not continue to rise over time. Rates of target-vessel MI and definite/probable scaffold thrombosis are significantly higher for the investigational device as compared with the metallic everolimus stent, but both risks appear to occur in the early period after device implantation, new data show. In a landmark analysis from 1 to 3 years, there was no significant difference in the risk of target...
Source: tctmd.com